Effects of Nonsurgical Periodontal Treatment on GCF Calprotectin and IL-10 in Rheumatoid Arthritis

Ondokuz Mayıs University54 enrolled

Overview

This study evaluates the relationship between rheumatoid arthritis and periodontal health and examines the effects of nonsurgical periodontal treatment on clinical periodontal findings and gingival crevicular fluid biomarkers. Participants with and without rheumatoid arthritis were classified according to periodontal status as periodontally healthy, gingivitis, or periodontitis. Clinical periodontal measurements and gingival crevicular fluid levels of calprotectin (MRP-8/14) and interleukin-10 (IL-10) were evaluated at baseline, 1 month, and 3 months. Disease Activity Score-28 (DAS28) was also evaluated in participants with rheumatoid arthritis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Rheumatoid Arthritis (RA)Periodontitis Gingivitis

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Voluntary participation in the study. Aged 18 to 65 years. For participants in the rheumatoid arthritis groups, diagnosis of rheumatoid arthritis at least 1 year before enrollment. For participants in the systemically healthy groups, absence of any systemic disease that may affect periodontal tissues. No periodontal treatment within the previous 6 months. No local or systemic antibiotic use within the previous 3 months. Never having smoked or having stopped smoking at least 2 years before enrollment. For participants in the periodontally healthy control groups, no history of periodontal disease and the presence of good oral hygiene. Exclusion Criteria: Unwillingness to participate in the study. Age younger than 18 years or older than 65 years. Presence of any systemic disease other than rheumatoid arthritis that may affect periodontal tissues. Local or systemic antibiotic use within the previous 3 months. Periodontal treatment within the previous 6 months. Pregnancy or lactation. Use of medications that may affect gingival tissues, including calcium channel blockers, phenytoin, cyclosporine, or hormone replacement therapy. Receiving biological treatment for rheumatoid arthritis, such as anti-tumor necrosis factor therapy. Current smoking.

Outcomes

Primary Outcomes

Change in Gingival Crevicular Fluid Calprotectin (MRP-8/14) Levels

Gingival crevicular fluid calprotectin (MRP-8/14) levels were measured using an enzyme-linked immunosorbent assay (ELISA). Changes in calprotectin levels were evaluated over time and compared according to rheumatoid arthritis status and periodontal condition.